Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
about
Functional and biological properties of the nuclear receptor coregulator PELP1/MNARExtranuclear coactivator signaling confers insensitivity to tamoxifenModulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cellsPELP1: A novel therapeutic target for hormonal cancersSignificance of ER-Src axis in hormonal therapy resistanceOncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptorVav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.Regulation of aromatase induction by nuclear receptor coregulator PELP1Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancerIntegration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.Cytoplasmic estrogen receptor in breast cancer.Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancerProteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.Emerging significance of ER-coregulator PELP1/MNAR in cancer.Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells.Exosome-bound WD repeat protein Monad inhibits breast cancer cell invasion by degrading amphiregulin mRNAEstrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss.Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.Molecular targets of breast cancer: AKTing in concertExpression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancerEstradiol-regulated microRNAs control estradiol response in breast cancer cells.Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.Drug resistance to targeted therapies: déjà vu all over againLoss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor.Complexity in endometrial estradiol signaling.Estrogen Receptors in Cell Membranes: Regulation and Signaling.Expression of NHERF1 in colonic tumors induced by 1,2-dimethylhydrazine in rats is independent of plasma ovarian steroids.Endocrine Resistance in Breast Cancer
P2860
Q24681766-1B17489C-7B92-448A-9550-B0A8E1DBD712Q28246263-531902B7-B36C-48C4-AD6F-730A7A426A1CQ28261025-B78E92DB-8FB4-4E83-8892-15EBCBFF9161Q28267811-BC0BB6A7-6803-46B6-833D-DAB0DDE591A5Q28301805-E3634EF4-74AB-4871-8283-BC53197B2690Q28304891-C2209B75-3BE2-478B-AE9E-0B7791908814Q33339736-4CC0C84A-60BE-48A1-908C-20440DBD2166Q33678686-938289CF-FEEC-4373-A718-2C9274F98963Q33750907-6ED87AB2-3A8A-4749-B2BA-183415D6D56AQ34533761-68F2A441-33E8-4F16-ABC5-6D7F742787FDQ34628232-7068A4B9-09BA-4BC8-BE38-B577DF4495C6Q34674316-37EA701C-8405-4618-B5D1-62E75DBA1BCDQ34908885-BED1167C-ED05-4A83-A063-297BE29F39FBQ35000307-35CBD4D8-FF75-4A13-A8E5-2220C2235AA5Q35624792-249F9D52-6F37-4AC9-B4FA-4526D24434F7Q35686728-1FAF0EF1-E8CB-426B-9437-41BD58980037Q36172210-C8721770-FD8D-494B-912F-DED71511F85BQ36245528-57E04029-AF54-4056-A62C-792ECC765418Q36245954-A48AEED4-3018-4FFB-87C7-1E06EB590BC1Q36665020-3DCF675D-BAB5-458D-98C2-F6984BB019E8Q36787062-DB420E50-4552-44EB-8D33-6A4363736F78Q36787353-025A3CC8-0F8D-48B9-ABE4-4419D8E637B2Q36790500-25596CDC-2BF2-47B1-B0E6-158106C12972Q36981139-23BB8870-C330-47A1-8235-EB817600B10BQ36983423-EA9FEED9-5E39-4ACB-B227-A39A7043E1ADQ37060140-EE7C2BCA-9C8D-4766-807C-0F6C29F50B61Q37183674-2EA8C263-BA9F-4B71-A88A-9EE30983A1CBQ37280705-22849211-3AF2-4DD3-9CB3-1E0A5E9620E2Q37298620-35BDE5D1-5EDF-425D-9DF7-115628F09926Q37911312-9886B51F-2CA9-47D5-B43E-59EC2180D45EQ38218657-7BC1E5BE-5B01-4C45-A517-7CF29DB1F01EQ38303667-E501C922-5E4A-41CA-A0E8-9D93D5CE7814Q42457894-10BC6774-F29C-4EC2-94AF-055BECF784B6Q46901888-7F3CE7EE-CC34-4777-9379-24B4761BD154Q47694885-28B78BC3-88D6-4997-AB8B-5612C56A95EDQ53284573-CA06184E-175C-405E-A761-55F0C29908F7Q59072640-813ABECE-1331-4DA3-8003-FE0B4383C5A8
P2860
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Novel mechanisms of resistance ...... and nongenomic considerations.
@ast
Novel mechanisms of resistance ...... and nongenomic considerations.
@en
type
label
Novel mechanisms of resistance ...... and nongenomic considerations.
@ast
Novel mechanisms of resistance ...... and nongenomic considerations.
@en
prefLabel
Novel mechanisms of resistance ...... and nongenomic considerations.
@ast
Novel mechanisms of resistance ...... and nongenomic considerations.
@en
P2093
P1476
Novel mechanisms of resistance ...... and nongenomic considerations.
@en
P2093
Anupama E Gururaj
Rakesh Kumar
Ratna K Vadlamudi
P304
1001s-1007s
P356
10.1158/1078-0432.CCR-05-2110
P407
P433
P577
2006-02-01T00:00:00Z